✉ Email this page to a colleague
« Back to Dashboard
GDC-0084 is an investigational drug.
There have been 186 clinical trials for GDC-0084. The most recent clinical trial was a Phase 3 trial, which was initiated on January 8th 2013.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lymphoma. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.
Recent Clinical Trials for GDC-0084
|Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer||National Cancer Institute (NCI)||Phase 1|
|Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma||National Cancer Institute (NCI)||Phase 1/Phase 2|
|Combination Therapy for the Treatment of Diffuse Midline Gliomas||Mithil Prasad Foundation||Phase 2|
Top disease conditions for GDC-0084
Top clinical trial sponsors for GDC-0084
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|GDC-0084||Argentina||AR084312||2030-12-16||See Plans and Pricing|
|GDC-0084||Australia||AU2011343712||2030-12-16||See Plans and Pricing|
|GDC-0084||Australia||AU2015268776||2030-12-16||See Plans and Pricing|
|GDC-0084||Brazil||BR112013014914||2030-12-16||See Plans and Pricing|
|GDC-0084||Canada||CA2820078||2030-12-16||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|